GB0314488D0 - Therapeutically useful compounds - Google Patents

Therapeutically useful compounds

Info

Publication number
GB0314488D0
GB0314488D0 GBGB0314488.8A GB0314488A GB0314488D0 GB 0314488 D0 GB0314488 D0 GB 0314488D0 GB 0314488 A GB0314488 A GB 0314488A GB 0314488 D0 GB0314488 D0 GB 0314488D0
Authority
GB
United Kingdom
Prior art keywords
therapeutically useful
useful compounds
compounds
therapeutically
useful
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0314488.8A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Priority to GBGB0314488.8A priority Critical patent/GB0314488D0/en
Publication of GB0314488D0 publication Critical patent/GB0314488D0/en
Priority to JP2006515980A priority patent/JP2007506664A/ja
Priority to EP04740011A priority patent/EP1636174A1/en
Priority to US10/561,055 priority patent/US7375248B2/en
Priority to PCT/EP2004/006553 priority patent/WO2004113279A1/en
Priority to US12/122,954 priority patent/US20080227858A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/42—Radicals substituted by singly-bound nitrogen atoms having hetero atoms attached to the substituent nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
GBGB0314488.8A 2003-06-20 2003-06-20 Therapeutically useful compounds Ceased GB0314488D0 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
GBGB0314488.8A GB0314488D0 (en) 2003-06-20 2003-06-20 Therapeutically useful compounds
JP2006515980A JP2007506664A (ja) 2003-06-20 2004-06-16 マトリックスメタロプロテイナーゼの阻害剤
EP04740011A EP1636174A1 (en) 2003-06-20 2004-06-16 Inhibitors of matrix metalloproteinase
US10/561,055 US7375248B2 (en) 2003-06-20 2004-06-16 Inhibitors of matrix metalloproteinase
PCT/EP2004/006553 WO2004113279A1 (en) 2003-06-20 2004-06-16 Inhibitors of matrix metalloproteinase
US12/122,954 US20080227858A1 (en) 2003-06-20 2008-05-19 Inhibitors of matrix metalloproteinase

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0314488.8A GB0314488D0 (en) 2003-06-20 2003-06-20 Therapeutically useful compounds

Publications (1)

Publication Number Publication Date
GB0314488D0 true GB0314488D0 (en) 2003-07-23

Family

ID=27637076

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0314488.8A Ceased GB0314488D0 (en) 2003-06-20 2003-06-20 Therapeutically useful compounds

Country Status (5)

Country Link
US (2) US7375248B2 (enExample)
EP (1) EP1636174A1 (enExample)
JP (1) JP2007506664A (enExample)
GB (1) GB0314488D0 (enExample)
WO (1) WO2004113279A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0321538D0 (en) * 2003-09-13 2003-10-15 Glaxo Group Ltd Therapeutically useful compounds
EA013539B1 (ru) 2005-02-22 2010-06-30 Рэнбакси Лабораториз Лимитед Производные 5-фенилпентановой кислоты в качестве ингибиторов матричной металлопротеиназы для лечения астмы и других заболеваний
JO2868B1 (en) 2006-08-22 2015-03-15 رانبكسي لابوراتوريز ليمتد Inhibitors of metabolic protein protein enzyme
WO2010056527A2 (en) * 2008-10-30 2010-05-20 Gilead Palo Alto, Inc. Fused heterocyclic compounds as ion channel modulators
US8987315B2 (en) 2009-12-31 2015-03-24 Innocrin Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
CN103209960A (zh) 2010-07-26 2013-07-17 百时美施贵宝公司 用作cyp17抑制剂的磺酰胺化合物
CN103119030A (zh) 2010-07-30 2013-05-22 兰贝克赛实验室有限公司 基质金属蛋白酶抑制剂
US20140148459A1 (en) 2010-09-24 2014-05-29 Ranbaxy Laboratories Limited Matrix metalloproteinase inhibitors
JP2013538821A (ja) 2010-09-24 2013-10-17 ランバクシー ラボラトリーズ リミテッド マトリックスメタロプロテイナーゼ阻害剤
EP2926808A1 (en) 2012-11-28 2015-10-07 Administración General De La Communidad Autónoma De Euskadi Use of metalloprotease inhibitors for the treatment of polycystic liver diseases

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS51139626A (en) 1975-05-29 1976-12-02 Sumitomo Chem Co Ltd A herbicide and a process for its preparation
AT368358B (de) * 1977-12-24 1982-10-11 Fisons Ltd Schaedlingsbekaempfungs- und pflanzenwachstumsregulierungsmittel
US5852192A (en) * 1992-03-11 1998-12-22 Dr. Karl Thomae Gmbh Cyclic urea derivatives, pharmaceutical compositions containing these compounds and processes for preparing them
US5863949A (en) * 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
US5710171A (en) * 1995-05-24 1998-01-20 Merck & Co., Inc. Bisphenyl inhibitors of farnesyl-protein transferase
EP0795550B1 (en) * 1996-03-11 2002-06-05 Sankyo Company Limited Aniline derivatives having herbicidal activity their preparation and their use
CZ294063B6 (cs) * 1996-05-17 2004-09-15 Warner-Lambert Company Bifenylsulfonamid, jeho použití a farmaceutický prostředek s jeho obsahem
WO1998009940A1 (en) * 1996-09-04 1998-03-12 Warner-Lambert Company Biphenyl butyric acids and their derivatives as inhibitors of matrix metalloproteinases
GB9801690D0 (en) * 1998-01-27 1998-03-25 Pfizer Ltd Therapeutic agents
JPH11236369A (ja) * 1998-02-23 1999-08-31 Kotobuki Seiyaku Kk スルホンアミド誘導体及びその製造法並びにこれを含有する医薬組成物
HK1047274A1 (zh) * 1999-07-01 2003-02-14 大正制药株式会社 氨基苯甲酸衍生物
US6451832B2 (en) * 1999-12-23 2002-09-17 Boehringer Ingelheim Pharma Kg Benzimidazoles with antithrombotic activity
AU4882101A (en) * 2000-04-28 2001-11-12 Shionogi & Co., Ltd. Mmp-12 inhibitors
JP2002205986A (ja) * 2000-11-08 2002-07-23 Takeda Chem Ind Ltd ピリミジン誘導体およびそれを含有する除草剤
JP2002193800A (ja) 2000-12-22 2002-07-10 Taisho Pharmaceut Co Ltd Ｖｅｇｆ受容体拮抗剤
JP2005504727A (ja) * 2001-04-13 2005-02-17 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド 抗炎症薬として有用なウレア化合物
GB0124928D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
WO2003035610A1 (en) * 2001-10-26 2003-05-01 Shionogi & Co., Ltd. Sulfonamide derivative having mmp inhibitory activity

Also Published As

Publication number Publication date
US20080227858A1 (en) 2008-09-18
US7375248B2 (en) 2008-05-20
JP2007506664A (ja) 2007-03-22
US20060142385A1 (en) 2006-06-29
WO2004113279A1 (en) 2004-12-29
EP1636174A1 (en) 2006-03-22

Similar Documents

Publication Publication Date Title
GB0309781D0 (en) Compounds
GB0305559D0 (en) Compounds
GB0314476D0 (en) Compounds
GB0304665D0 (en) Compounds
EP1689403A4 (en) HETEROARYL-hydrazone compounds
GB0314478D0 (en) Compounds
GB0305553D0 (en) Compounds
GB0313915D0 (en) Compounds
GB0306329D0 (en) Compounds
GB0313914D0 (en) Compounds
EP1682514A4 (en) 11-O-METHYLGELDANAMYCIN COMPOUNDS
GB0319069D0 (en) Therapeutically useful compounds
GB0302512D0 (en) Compounds
GB0304494D0 (en) Compounds
GB0320988D0 (en) Therapeutically useful compounds
GB0321108D0 (en) Therapeutically useful compounds
GB0208025D0 (en) Therapeutically useful compounds
GB0226676D0 (en) Therapeutically useful compounds
GB0213770D0 (en) Therapeutically useful compounds
GB0210145D0 (en) Therapeutically useful compounds
GB0219246D0 (en) Therapeutically useful compounds
GB0314477D0 (en) Compounds
GB0310067D0 (en) Compounds
GB0310069D0 (en) Compounds
GB0302543D0 (en) Compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)